Trial reportJournal of cardiothoracic surgery2021
Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.
Trial report in Journal of cardiothoracic surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized, Multicenter, International, Open-Label Clinical Trial Comparing Drug-Coated Balloon and Drug-Eluting Stent for the Treatment of Acute ST-Elevation Myocardial Infarction.
The Safety and Efficacy of New-Generation Bioabsorbable Scaffolds Versus Drug-Coated Balloons in the Treatment of De Novo Lesions in Large Coronary Arteries: A Prospective Randomized Controlled Study
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Drug Coated Balloons Versus Drug-Eluting Stents in Patients With De Novo Coronary Artery Disease.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Pooled it
- Drug-coated balloon versus drug-eluting stent for treating de novo large vessel coronary artery disease: a systematic review and meta-analysis of 13 studies involving 2888 patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Pooled it
- Comparison of Efficacy and Safety Between Drug-Coated Balloons Versus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions in Large Vessels: A Study-Level Meta-Analysis of Randomized Control Trials.Cardiovascular drugs and therapy · 2024Pooled it
- Drug-Coated Balloon vs. Drug-Eluting Stent in Acute Myocardial Infarction: A Systematic Review and Updated Meta-Analysis.Anatolian journal of cardiology · 2023Pooled it
- Comparison of Drug-Coated Balloons and Drug-Eluting Stents in Primary Percutaneous Coronary Interventions for ST-Segment Elevated Myocardial Infarction: A Systemic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2022Pooled it
- Drug-Coated Balloons for Acute Myocardial Infarction: A Metaanalysis of Randomized Clinical Trials.Journal of interventional cardiology · 2022Pooled it
- Regional Differences Between Drug-Coated Balloons and Drug-Eluting Stents inCardiology research · 2026Article
- Drug-coated balloon angioplasty for coronary and peripheral artery disease: latest evidence and clinical indications.Nature reviews. Cardiology · 2026Review
- Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials.Health science reports · 2026Article
- Drug-Coated Balloon in Acute Coronary Syndromes: Ready for the Prime Time?Current cardiology reports · 2024Review
- Cardiovascular Outcomes after Paclitaxel-Coated Balloon Angioplasty versus Drug-Eluting Stent Placement for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Paclitaxel-eluting stents versus paclitaxel-coated balloons in coronary artery disease: a meta-analysis of randomized controlled trials.Global cardiology science & practice · 2024Review
- Article
- Exploring alternatives to drug-eluting stents: the potential of combining drug coated balloon with bare-metal stents.Cardiovascular diagnosis and therapy · 2023Article
- Efficacy and Prediction Model Construction of Drug-Coated Balloon Combined with Cutting Balloon Angioplasty in the Treatment of Drug-Eluting Stent In-Stent Restenosis.Computational and mathematical methods in medicine · 2022Article
- CircLMTK2 Silencing Attenuates Gemcitabine Resistance in Pancreatic Cancer by Sponging miR-485-5p and to Target PAK1.Journal of oncology · 2022Article
- Correction to: Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.Journal of cardiothoracic surgery · 2021Article
- Paclitaxel- and Sirolimus-Coated Drug-Coated Balloons versus Drug-Eluting Stents in Acute Myocardial Infarction: A Comprehensive Systematic Review and Meta-Analysis.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.
methodWe selected 80 patients admitted to the hospital for STEMI from January 2018 to December 2019. The subjects were randomly divided into a Yinyi (Liaoning) Biotech Bingo Drug Coated Balloon treatment group (balloon group, n = 38) and a drug-eluting stent (DES) treatment group (stent group, n = 42). Patients were followed up to understand the incidence of major adverse cardiovascular events (MACE) at 1 month, 6 months and 1 year after surgery. Coronary angiography was rechecked 1 year after surgery to understand the late lumen loss (LLL) in the two groups.
resultDuring the one-year follow-up, the LLL of the target lesion in the balloon group was -0.12±0.46 mm, while the target lesion in the stent group was 0.14±0.37 mm ( P <0.05). Within 1 year, the incidence of MACE in the balloon group was 11%, while the incidence of MACE in the stent group was 12%. There was no significant difference between the two groups. IN
conclusionWhen PCI is used for STEMI, only DCB therapy is safe and effective, and has shown good clinical effects during a one-year follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.